 The objective of this study was to re-analyze the patient-level data set of the sequence treatment alternatives to relieve depression, stard, study with fidelity to the original research protocol and related publications. The study was open-label and semi-randomized, examining the effectiveness of up to four optimized and increasingly aggressive, antidepressant therapies in depressed adults. Patients who failed to gain adequate relief from their level one trial on the SSI Sitalopram could receive up to three additional treatment trials in levels two to four. The study enrolled patients seeking care, VS recruited, and included patients with a wide range of common comorbid medical and psychiatric conditions to enhance the generalizability of findings to real-world clinical practice. Interventions included 13 antidepressant therapies in treatment levels two to four for depressed patients who failed to gain adequate benefit from their level one medication trial. The primary outcome measure was remission, defined as a score less than or equal to eight on the blinded Hamilton rating scale for depression, HRSD. This article was authored by Irving Kirsch, H. Edmund Piggott, Thomas Kim, and others. We are article.tv, links in the description below.